

[View this email in your browser](#)



Canadian Children Inflammatory Bowel Disease Network

## December 2023 Newsletter



The Publications Policy and Publications Submission & Approval Roadmap can be downloaded on the [website](#). **Please plan for at least 5 working days for abstract review by co-authors prior to submission.**

Remember to notify CIDsCaNN when your abstract or manuscript is accepted for publication.

**When that acceptance email comes in, please forward it to Michelle ([michelle.ouzounis@sickkids.ca](mailto:michelle.ouzounis@sickkids.ca)).**

Having a full list of publications is important when compiling year-end reports, and will help us make our research more broadly available via the website.



## From the CIDsCaNN Executive Committee

We're very pleased to welcome our newest Co-Chair Elect, Eileen Crowley, to the Executive Committee! Eileen joins Co-Chairs, Jennifer deBruyn and Eytan Wine.

Please join us in extending our heartfelt thanks to David Mack for his leadership and dedication on the Executive Committee, as he steps down as Co-Chair.

Thank you to everyone who attended our Annual CIDsCaNN Face-to-Face Meeting in Toronto in November.

It was a wonderful opportunity for members and staff from across Canada to gather, and hear updates on the amazing work being done. We appreciate everyone's efforts to be there with us!



## Important Reminders


- The CIDsCaNN shared documents [Dropbox](#) has logo files and branded powerpoint templates for member use.
- We encourage CIDsCaNN members and trainees to develop research protocols, abstracts and publications using information from the CIDsCaNN database. Find information on the [Governance & Policies](#) webpage.
- Did you know? Conference travel funds are available for trainees and early-stage investigators who submit and present abstracts of CIDsCaNN data. Find the application form [on the website](#).

## How to submit a proposal


Have a great idea for a project?  
CIDsCaNN is here to help!

Visit the website for information,  
including sample proposals, forms and  
contacts.

[Learn more](#)



## Current Projects



Phase 2 CIDsCaNN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF Inhibitors in biologic-naïve Crohn’s Disease

Inclusion criteria: Children age 2-17y with Crohn’s disease starting first biologic as antiTNF or UST for luminal Crohn’s disease

Participating sites: All

Target: 200 antiTNF, 100 UST

AMBITION-CD Site Lead Meetings take place the second Tuesday of each month.

We have officially passed the halfway point for total recruitment and anti-tnf!

anti-TNF: 110/200  
ustekinumab: 42/100

Next site leads meeting will be January 9, 3-4pm EST

Contact: Hayley [hayley.mckay@sickkids.ca](mailto:hayley.mckay@sickkids.ca)

Contact: Michelle [michelle.ouzounis@sickkids.ca](mailto:michelle.ouzounis@sickkids.ca)

Site	Enrolled in AMBITION-CD	Biologic	
		Ustekinumab	Anti TNF
Calgary	8	6	2
Ottawa	18	1	17
Montreal	3	2	1
Ste Justine	4	3	1
Vancouver	20	0	20
Toronto	54	12	42
London	18	4	14
Edmonton	23	14	9
Halifax	7	2	5
St Johns	2	0	2
Winnipeg	16	3	13
McMaster	1	1	0
<b>Total</b>	<b>174</b>	<b>48</b>	<b>126</b>

## Education Update

**NEW!** You can now subscribe to be notified of Education sessions. This is intended to help us keep track of registration, and notify participants of cancellations or changes.

All you need to do is visit the website and fill in a short form.

### Up-coming education sessions:

**January 16, 2024 — Session 9: Transition from Pediatric to Adult Care in IBD: What Can CIDSCaNN Do To Improve Care?** Lead by Dr. Sara Ahola Kohut & Dr. Eric Benchimol

**February 13, 2024 — Session 10: Challenging IBD Case-Based Discussion**  
Lead by: TBA Supported by: CIDSCaNN Education Committee

Most recent session:

Session 8: Positioning & Sequencing Advanced Therapies in PIBD ([watch the recording here](#))

Please respond to the Education Committees' survey about future topics! As we take your topic suggestions very seriously, you may see one of your topic ideas show up during future sessions. Thank you very much for your ongoing engagement and ideas!

We encourage you to share the Education Session calendar invites with your multidisciplinary teams. Please find the dates for future sessions, and past recordings at [cidscann.ca/education](https://cidscann.ca/education)

[Go to the website](#)






**Congratulations to David Mack, recipient of the Crohn's and Colitis Canada 2023 Research Leadership Award!**


Nominated by their fellow scientists, recipients of the Research Leadership Award have made an exceptional contribution to Crohn's and Colitis Canada's Promise to cure Crohn's disease and ulcerative colitis and improve the lives of children and adults living with these chronic diseases.

---

[Outcomes Following Acute Severe Colitis at Initial Presentation](#) has been published in JCC (August 2023). Congratulations to lead authors Jasbir Dhaliwal and Anne Griffiths, and thank you to all those who contributed to this study!



Adalimumab vs Infliximab in Luminal Pediatric Crohn’s Disease has been published in the October issue of AJG. Congratulations to lead authors Thom Walters and Jennifer deBruyn, and thank you to all who contributed to this study!



**DID YOU KNOW?** If you need assistance creating a graphic abstract like this one for publication, you can email Communications at [heather.dyer@ucalgary.ca](mailto:heather.dyer@ucalgary.ca)



**Thank you for your engagement and  
contribution to CIDsCaNN!**

## PARTICIPATING SITES



*Copyright (C) 2023 Canadian Children Inflammatory Bowel Disease Network. All rights reserved.*

Contact:

555 University Avenue, Toronto ON Canada M5G 1X8

Email: [info@cidscann.ca](mailto:info@cidscann.ca)

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe](#)